The human immunodeficiency virus (HIV) is a lentivirus that causes chronic viral infection. HIV damages the immune system and prevents the body from fighting off the organisms that cause infection and disease. Without early diagnosis and treatment of HIV, the body can go on to develop AIDS. Acquired immunodeficiency syndrome (AIDS) is the final stage of HIV. The development of AIDS interferes with the body’s ability to fight off any life threatening infection.

HIV is most commonly a sexually transmitted infection. However, it can also be contracted through contact with infected blood or from mother to child during pregnancy, childbirth or breast feeding (vertical transmission).

This report provides the current prevalent population for HIV across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of HIV have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for HIV include:

• Impaired kidney function
• Aids
• Opportunistic infections
• HBC
• HCV

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global HIV market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of HIV and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on the HIV prevalent population.
• Identify sub-populations within HIV which require treatment.
• Gain an understanding of the specific markets that have the largest number of HIV patients.